CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
Zabaleta N, Barberia M, Martin-Higueras C, Zapata-Linares N, Betancor I, Rodriguez S, Martinez-Turrillas R, Torella L, Vales A, Olagüe C, Vilas-Zornoza A, Castro-Labrador L, Lara-Astiaso D, Prosper F, Salido E, Gonzalez-Aseguinolaza G, Rodriguez-Madoz JR.
Zabaleta N, et al. Among authors: rodriguez s, rodriguez madoz jr.
Nat Commun. 2018 Dec 21;9(1):5454. doi: 10.1038/s41467-018-07827-1.
Nat Commun. 2018.
PMID: 30575740
Free PMC article.